Last reviewed · How we verify
NCT06009705: Best-EEC
Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer
trial testing toripalimab in Esophageal Carcinoma in 56 participants. Currently enrolling.
30 April 2025
Quick facts
| Lead sponsor | Hebei Medical University Fourth Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 56 |
| Start date | 1 October 2022 |
| Primary completion | 30 April 2025 |
| Estimated completion | 30 April 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- toripalimab (TORIPALIMAB) — full drug profile →
Conditions studied
- Esophageal Carcinoma — all drugs for Esophageal Carcinoma →
Sponsor
Hebei Medical University Fourth Hospital
Who can join
65 and older, any sex, with Esophageal Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial aims to assess efficacy and safety of toripalimab combined with radiotherapy and S-1 followed by adjuvant toripalimab maintenance therapy for older patients with stage II-III esophageal cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06009705
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of toripalimab
Trials testing the same drug.
- NCT07245901 — Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Mo · Phase 1, PHASE2 · not yet recruiting
- NCT07177794 — Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC · Phase 3 · not yet recruiting
- NCT06283303 — A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer · Phase 1 · unknown
- NCT06283121 — A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer · Phase 2 · not yet recruiting
- NCT05635643 — Study of CHS-114 in Participants With Advanced Solid Tumors · Phase 1 · recruiting
Other recruiting trials for Esophageal Carcinoma
Currently open trials in the same condition.
- NCT07283939 — Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays · NA · recruiting
- NCT07108855 — Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green Duri · Phase 1, PHASE2 · recruiting
- NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
- NCT06872515 — Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal) · NA · recruiting
- NCT06995898 — The Vanguard Study: Testing a New Way to Screen for Cancer · NA · recruiting
Other Hebei Medical University Fourth Hospital trials
Trials by the same sponsor.
- NCT05522491 — Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Br · Phase 2 · not yet recruiting
- NCT07448077 — Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC · Phase 2 · not yet recruiting
- NCT07410611 — ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy · Phase 2 · not yet recruiting
- NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting
- NCT07492394 — Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06009705 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hebei Medical University Fourth Hospital
- Last refreshed: 24 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06009705.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing